Document is current

Article History

Received: 9 July 2025

Accepted: 28 October 2025

First Online: 15 November 2025

Change Date: 30 January 2026

Change Type: Update

Change Details: In the original version of this article, several citation callouts were incorrect.

Change Details: In the Results section, the sentence originally reading: “Re-analysis of single-cell RNA-sequencing data from a genetically engineered PDAC mouse model₅₅ further confirmed Klf5 upregulation during disease initiation, and demonstrated that Klf5 expression is sustained throughout disease progression (Figs. 1D, S1F)_46,47” should not include refs. 46 and 47 at the end.

Change Details: In the Discussion section, the sentence originally reading: “KLF5 is known to be induced during pancreatic inflammation and stabilized by mutant KRAS to drive acinar-to-ductal metaplasia_36,40. Additionally, prior work implicates KLF5 in sustaining classical PDAC lineage identity41" should instead cite refs. 34, 38 and 39.

Change Details: In the Discussion section, the sentence originally reading: “Several studies have demonstrated that pharmacological targeting of RUVBL1/2 can extend the survival of tumor-bearing mice, although the mechanisms that underlie a tumor-specific dependence on RUVBL1/2 ATPase activity are unclear_49,51,52,76” should instead cite refs. 49, 50, 51, and 76.

Change Details: These errors have been corrected in the HTML and PDF versions of the article.

Competing interests

: C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer-Ingelheim and Treeline Biosciences; and owns a stock option from Treeline Biosciences. M.E. owns stock in Agios Pharmaceuticals. The remaining authors declare no competing interests.